This compound is an amino-substituted quinazoline derivative used as a pharmaceutical intermediate in the manufacturing of afatinib-related impurities. It is characterized by the presence of aromatic rings, amine groups, and halogen atoms.
Portée du contenu: Les informations de cette page concernent l'identification chimique ainsi que les contextes d'approvisionnement industriel, de recherche et de production. Elles ne constituent ni une allégation thérapeutique, ni un avis médical, ni une notice d'utilisation médicamenteuse.
Approvisionnement ou fourniture de ce composé?
Publiez votre inventaire ou une demande d'achat
CAS 1449430-53-8
(S)-N4-(3,4-Dichlorophenyl)-7-((tetrahydrofuran-3-yl)oxy)quinazoline-4,6-diamine
pharmaceutical intermediate for afatinib impurities
7-fluoro-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one
pharmaceutical intermediate
1-(1,1-Dimethylethyl) 2-ethyl (2S)-5-oxo-1,2-pyrrolidinedicarboxylate
Pharmaceutical intermediate for peptide synthesis
1-Boc-D-Pyroglutamic acid ethyl ester
Pharmaceutical intermediate
(S)-3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-methoxy-4-oxobutanoic acid
Protected amino acid for peptide synthesis
(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-hydroxyquinazolin-6-yl)-4-(dimethylamino)but-2-enamide
active pharmaceutical ingredient
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-nitroquinazolin-4-amine
Pharmaceutical intermediate for kinase inhibitors
Chlorhydrate d'erlotinib
active pharmaceutical ingredient
6-amino-4-(3-chloro-4-fluoroanilino)quinazolin-7-ol
YEFNIUDZICAGOU-UHFFFAOYSA-N
C1=CC(=C(C=C1NC2=NC=NC3=CC(=C(C=C32)N)O)Cl)F